These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3002264)

  • 21. Inhibitory activity of oxyresveratrol on wild-type and drug-resistant varicella-zoster virus replication in vitro.
    Sasivimolphan P; Lipipun V; Likhitwitayawuid K; Takemoto M; Pramyothin P; Hattori M; Shiraki K
    Antiviral Res; 2009 Oct; 84(1):95-7. PubMed ID: 19635502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acyclovir treatment prevents varicella-zoster virus replication in PBMC during viremia.
    Wolff MH; Schünemann S
    New Microbiol; 1999 Oct; 22(4):309-14. PubMed ID: 10555200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herpes simplex virus type 1 that exhibits herpes simplex virus type 2 sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Docherty JJ; Dobson AT; Trimble JJ; Jennings BA
    Intervirology; 1991; 32(5):308-15. PubMed ID: 1657822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs.
    De Clercq E; Walker RT
    Pharmacol Ther; 1984; 26(1):1-44. PubMed ID: 6099893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiherpes activity of 5-(2-bromoethyl)-2'-deoxyuridine.
    La Colla P; Gelli G; Mura L; Landini MP; Corrias MV; Pani A; Marongiu ME
    Antiviral Res; 1985; Suppl 1():29-34. PubMed ID: 3002262
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antiviral resistance of herpes simplex virus and varicella-zoster virus].
    Daikoku T; Shiraki K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():480-6. PubMed ID: 17455667
    [No Abstract]   [Full Text] [Related]  

  • 27. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster.
    Breuer J; Whitley R
    Herpes; 2007 Sep; 14 Suppl 2():25-9. PubMed ID: 17939892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of mutations in the thymidine kinase gene of varicella zoster virus associated with resistance to 5-iodo-2'-deoxyuridine and 5-bromo-2'-deoxyuridine.
    Kodama E; Mori S; Shigeta S
    Antiviral Res; 1995 May; 27(1-2):165-70. PubMed ID: 7486953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of antiviral assay methods using cell-free and cell-associated varicella-zoster virus.
    Shiraki K; Ochiai H; Namazue J; Okuno T; Ogino S; Hayashi K; Yamanishi K; Takahashi M
    Antiviral Res; 1992 Jun; 18(2):209-14. PubMed ID: 1329651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Controlling herpes zoster. End end to bullae].
    MMW Fortschr Med; 2001 May; 143(22):50. PubMed ID: 11460405
    [No Abstract]   [Full Text] [Related]  

  • 31. Selection of L cell sublines resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Shiraki K; Vonka V; De Clercq E; Rapp F
    Intervirology; 1991; 32(4):228-33. PubMed ID: 1650764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the treatment of varicella-zoster virus infections.
    Andrei G; Snoeck R
    Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory effects of antiherpesviral thymidine analogs against varicella-zoster virus.
    Machida H; Kuninaka A; Yoshino H
    Antimicrob Agents Chemother; 1982 Feb; 21(2):358-61. PubMed ID: 6280604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus.
    Biron KK; Fyfe JA; Noblin JE; Elion GB
    Am J Med; 1982 Jul; 73(1A):383-6. PubMed ID: 6285728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    De Clercq E
    J Antimicrob Chemother; 1984 Aug; 14 Suppl A():85-95. PubMed ID: 6092320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.
    Yokota T; Konno K; Shigeta S; Verbruggen A; De Clercq E
    Mol Pharmacol; 1987 May; 31(5):493-9. PubMed ID: 3033468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro.
    Biron KK; Elion GB
    Am J Med; 1982 Jul; 73(1A):54-7. PubMed ID: 6285733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization.
    Fillet AM; Dumont B; Caumes E; Visse B; Agut H; Bricaire F; Huraux JM
    J Med Virol; 1998 Jul; 55(3):250-4. PubMed ID: 9624615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral therapy of herpes simplex and varicella-zoster virus infections.
    Wutzler P
    Intervirology; 1997; 40(5-6):343-56. PubMed ID: 9675639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of BVDU: An odyssey.
    De Clercq E
    Antivir Chem Chemother; 2023; 31():20402066231152971. PubMed ID: 36710501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.